The KDM1A histone demethylase is a promising new target for the epigenetic therapy of medulloblastoma.

ABSTRACT:

Background

Medulloblastoma is a leading cause of childhood cancer-related deaths. Current aggressive treatments frequently lead to cognitive and neurological disabilities in survivors. Novel targeted therapies are required to improve outcome in high-risk medulloblastoma patients and quality of life of survivors. Targeting enzymes controlling epigenetic alterations is a promising approach recently bolstered by the identification of mutations in histone demethylating enzymes in medulloblastoma sequencing efforts. Hypomethylation of lysine 4 in histone 3 (H3K4) is also associated with a dismal prognosis for medulloblastoma patients. Functional characterization of important epigenetic key regulators is urgently needed.

Results

We examined the role of the H3K4 modifying enzyme, K

SUBMITTER: Pajtler KW 

PROVIDER: S-EPMC3893444 | biostudies-literature | 2013 May

REPOSITORIES: biostudies-literature